Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii
Frontiers in Cellular and Infection Microbiology · 18.07.2024 · 14
DOI: 10.3389/fcimb.2024.1395260 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 18.07.2024. Verfasst von Siqin Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Hangzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Acinetobacter Infections, Carbapenems, Anti-Bacterial Agents. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Science and Technology Project of Zhejiang Province.
Abstract (Originalsprache)
Patients with severe carbapenem-resistant Acinetobacter baumannii (CRAB) infections currently face significant treatment challenges. When patients display signs of infection and the clinical suspicion of CRAB infections is high, appropriate treatment should be immediately provided. However, current treatment plans and clinical data for CRAB are limited. Inherent and acquired resistance mechanisms, as well as host factors, significantly restrict options for empirical medication. Moreover, inappropriate drug coverage can have detrimental effects on patients. Most existing studies have limitations, such as a restricted sample size, and are predominantly observational or non-randomized, which report significant variability in patient infection severity and comorbidities. Therefore, a gold-standard therapy remains lacking. Current and future treatment options of infections due to CRAB were described in this review. The dose and considerable side effects restrict treatment options for polymyxins, and high doses of ampicillin-sulbactam or tigecycline appear to be the best option at the time of initial treatment. Moreover, new drugs such as durlobactam and cefiderocol have substantial therapeutic capabilities and may be effective salvage treatments. Bacteriophages and antimicrobial peptides may serve as alternative treatment options in the near future. The advantages of a combination antimicrobial regimen appear to predominate those of a single regimen. Despite its significant nephrotoxicity, colistin is considered a primary treatment and is often used in combination with antimicrobials, such as tigecycline, ampicillin-sulbactam, meropenem, or fosfomycin. The Infectious Diseases Society of America (IDSA) has deemed high-dose ampicillin-sulbactam, which is typically combined with high-dose tigecycline, polymyxin, and other antibacterial agents, the best option for treating serious CRAB infections. A rational combination of drug use and the exploration of new therapeutic drugs can alleviate or prevent the effects of CRAB infections, shorten hospital stays, and reduce patient mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Hangzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China.
- Department of Clinical Laboratory, Tongxiang First People's Hospital, Tongxiang, Zhejiang, China.
- Panvascular Diseases Research Center, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, China.
Förderung
- Medical Science and Technology Project of Zhejiang Province
Zitieren
APA
Zhang, S., Di, L., Qi, Y., Qian, X., & Wang, S. (2024). Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii. Frontiers in Cellular and Infection Microbiology, 14. https://doi.org/10.3389/fcimb.2024.1395260
Vancouver
Zhang S, Di L, Qi Y, Qian X, Wang S. Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii. Frontiers in Cellular and Infection Microbiology. 2024;14. doi:10.3389/fcimb.2024.1395260
BibTeX
@article{Zhang2024,
author = {Zhang, Siqin and Di, Lingfang and Qi, Yan and Qian, Xiang and Wang, Siwei},
title = {Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2024},
volume = {14},
doi = {10.3389/fcimb.2024.1395260}
}
EUVIMED